A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

NCT06936644 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
39
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Chest Hospital

Collaborators